919 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint http://www.zacks.com/stock/news/260624/lillys-migraine-drug-phase-iii-trials-meet-primary-endpoint?cid=CS-ZC-FT-260624 May 15, 2017 - Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies
3 Reasons I Am Upgrading Target Price On Teva Pharmaceuticals https://seekingalpha.com/article/4073208-3-reasons-upgrading-target-price-teva-pharmaceuticals?source=feed_sector_healthcare May 15, 2017 - Teva reported a strong first quarter. Company on track to launch many new products this year. Management simultaneously cutting debt and maintaining dividend rate.
Francis Chou Buys Endo International PLC, Teva Pharmaceutical Industries, Valeant ... http://www.gurufocus.com/news/519980/francis-chou-buys-endo-international-plc-teva-pharmaceutical-industries-valeant-pharmaceuticals-international-inc-sells-nokia-oyj-astrazeneca-plc-glaxosmithkline-plc May 12, 2017 - Francis Chou Buys Endo International PLC, Teva Pharmaceutical Industries, Valeant Pharmaceuticals International Inc, Sells Nokia Oyj, AstraZeneca PLC, GlaxoSmithKline PLC, Stocks: VRX,SD,SD,ENDP,TEVA,NOK,AZN,GSK,, release date:May 12, 2017
Here's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets https://www.fool.com/investing/2017/05/12/heres-how-much-teva-pharmaceutical-could-net-from.aspx?source=iedfolrf0000001 May 12, 2017 - Teva's Women's Health operations and its European oncology and pain divisions appear to be on the chopping block.
Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls http://www.zacks.com/stock/news/260350/teva-teva-q1-earnings-in-line-sales-lag-as-copaxone-falls?cid=CS-ZC-FT-260350 May 12, 2017 - Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study http://www.zacks.com/stock/news/260392/pharma-stock-roundup-mylan-teva-q1-earnings-roche-drug-misses-in-pivotal-study?cid=CS-ZC-FT-260392 May 12, 2017 - While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
Teva Pharmaceutical Industries' (TEVA) CEO Yitzhak Peterburg on Q1 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4072511-teva-pharmaceutical-industries-teva-ceo-yitzhak-peterburg-q1-2017-results-earnings-call?source=feed_sector_healthcare May 12, 2017 - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Q1 2017 Results Earnings Conference Call May 11, 2017 08:00 AM ET Executives Kevin Mannix - SVP and Head of IR Sol Barer - Chairman Yitzhak Peterburg -
Teva to jettison women's health and European oncology and pain units; shares ahead 2% https://seekingalpha.com/news/3266554-teva-jettison-womens-health-european-oncology-pain-units-shares-ahead-2-percent?source=feed_news_all May 11, 2017 - During its Q1 earnings call, Teva Pharmaceutical Industries (TEVA +1.9%) interim CEO Yitzhak Peterburg confirmed that the company intends to shop its women's heath and European oncology and pain busin
Actavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher https://www.fool.com/investing/2017/05/11/actavis-generics-acquisition-drives-teva-pharmaceu.aspx?source=iedfolrf0000001 May 11, 2017 - The specialty and generic drugmaker gets another boost from its 2016 purchase of Actavis Generics from Allergan.
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan http://www.zacks.com/stock/news/260286/impax-ipxl-q1-earnings-miss-stock-up-on-cost-savings-plan?cid=CS-ZC-FT-260286 May 11, 2017 - Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

Pages: 1...7879808182838485868788...92

<<<Page 83>